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Abstract:  
Disease bulk is an important prognostic factor in early stage Hodgkin lymphoma, but its 
definition is unclear in the computed tomography-era. This retrospective analysis investigated 
the prognostic significance of bulky disease measured in transverse and coronal planes on 
computed tomography imaging. Early stage Hodgkin lymphoma patients (n=185) treated with 
chemotherapy with or without radiotherapy from 2000-2010 were included. The longest diameter 
of the largest lymph node mass was measured in transverse and coronal axes on pre-treatment 
imaging. The optimal cutoff for disease bulk was maximal diameter greater than 7 cm measured 
in either the transverse or coronal plane. Thirty patients with maximal transverse diameter ≤7 cm 
were found to have bulk in coronal axis.  The 4-year overall survival was 96.5% (CI 93.3%, 
100%) and 4-year relapse-free survival was 86.8% (CI 81.9%, 92.1%) for all patients.  Relapse 
free survival at 4-years for bulky patients was 80.5% (CI 73%, 88.9%) compared to 94.4% (CI 
89.1%, 100%) for non-bulky, Cox HR 4.21 (CI 1.43, 12.38), P = 0.004. In bulky patients, relapse 
free survival was not impacted in patients treated with chemoradiotherapy; however, was 
significantly inferior in patients treated with chemotherapy alone. In an independent validation 
cohort of 38 patients treated with chemotherapy alone, patients with bulky disease had an 
inferior relapse-free survival (at 4-years, 71.1% (CI 52.1%, 97%) versus 94.1% (CI 83.6%, 
100%), Cox HR 5.27 (CI 0.62, 45.16), P = 0.09). Presence of bulky disease on multidimensional 
computed tomography imaging is a significant prognostic factor in early stage Hodgkin 
lymphoma. Coronal reformations may be included for routine Hodgkin lymphoma staging 
evaluation. In future, our definition of disease bulk may have utility in identifying patients who 
are most appropriate for chemotherapy-alone.   
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Introduction 
 The presence of bulky disease at presentation has long been considered a poor prognostic 
factor in early stage Hodgkin lymphoma (ESHL).1, 2 Historically, bulk in the mediastinum was 
focused upon and defined using radiographic criteria from a standing posterior-anterior (PA) 
chest radiograph (CXR). In the 1989 Cotswolds revision of the Ann Arbor Staging system bulk 
in the mediastinum was defined as, “when the maximum width is equal or greater than one-third 
of the internal transverse diameter of the thorax at the level of T5/6” on a PA CXR and bulk at an 
alternate site was defined as any mass measuring ≥10 cm by any imaging study. 3  Today the 
presence of bulky disease in ESHL remains an unfavorable prognostic feature in all modern risk 
classification systems, but is variably defined as >1/3 of the mediastinal mass ratio (MMR), >1/3 
of the mediastinal thoracic ratio (MTR), or any mass >10 cm.4-7  
   Although definitions of disease bulk were originally developed in the CXR-era, computed 
tomography (CT) imaging is now the standard staging imaging modality in lymphoma.8 In the 
CT era, the definition of disease bulk remains elusive. Various retrospective studies have defined 
CT criteria for bulky disease associated with increased risk of relapse in ESHL, ranging from 
greater than 5 to 10 cm for the maximal mediastinal mass diameter in transverse plane.9-11 The 
recent “Lugano Classification” for initial staging in lymphoma retains the historical definition of 
bulk with a single nodal mass of ≥10 cm or mediastinal bulk >1/3 of the transthoracic diameter. 
However, with uncertainty regarding an evidence-based definition of bulk in the CT-era, the 
authors also suggest elimination of the modifier “X” and propose recording the longest 
measurement by CT scan, presumably in the transverse plane.8 However, there remains a critical 
need for a bulky disease cut-point in ESHL as increasingly patients are being treated with 
chemotherapy alone to avoid the late-effects of radiotherapy, an approach that has generally 
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excluded patients with disease bulk.12, 13  For example, the recently published UK RAPID study 
included stage IA and IIA patients without mediastinal bulk defined as maximal mediastinal 
diameter ≥33% of the internal thoracic diameter at T5–T6.12  
 Importantly, the transverse diameter of a lymph node mass may not reflect the longest 
dimension of an obliquely or sagittally positioned mass in HL. On CT, lymph node masses can 
be measured in the transverse, coronal, and sagittal planes, however, measurements in axes other 
than the transverse are rarely reported in HL, and 3-dimensional or volumetric assessments of 
tumor bulk are difficult to routinely assess. In this study, we aimed to assess the prognostic 
significance of the longest diameter of the largest nodal mass measured in either the transverse 
and coronal planes using CT imaging.   
 
Methods 
Patients 
For the training cohort of this retrospective study, we identified pediatric and adult 
patients with stage I-II classical HL treated at Memorial Sloan Kettering (MSK) Cancer Center 
between January 2000 and December 2010. Patients were included if they had pre-treatment CT 
scan performed within 30 days of therapy initiation and received doxorubicin-containing 
chemotherapy with or without radiation at MSK.  
For the independent validation cohort, adult patients with classical HL, stage I-II, with 
baseline CT scan performed within 30 days of therapy, and treated with chemotherapy alone at 
Dana Farber Cancer Institute (DFCI) or Mayo Clinic (Mayo) between January 2000 and 
December 2010 were included. These retrospective analyses were conducted on waivers of 
authorization approved by the institutional review boards at each institution.  
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Radiologic Assessment 
Measurements for the training cohort were performed by a single board-certified 
radiologist (I.B.) who was blinded to patients’ clinical history, including treatment and outcome. 
All available pretreatment imaging studies, including diagnostic computed tomography (dCT), 
FDG-PET and FDG-PET/CT were reviewed.  CT scans were performed on GE Lightspeed 
helical scanners. MSK patients were scanned on dedicated PET/CT systems (Discovery STE, LS 
or 690 [GE Medical Systems] or Biograph 16 [Siemens Medical Systems]). Images were 
reconstructed at 5 or 7.5-mm intervals in the Picture Archiving and Communication System 
(PACS) (Centricity; GE Medical Systems, Milwaukee, WI). CT scans from outside institutions 
were digitized on PACS, reviewed and included only if of acceptable quality. Most 
measurements were obtained using dCT (134 of 185, 72%). Others were from low-dose CT 
performed in conjunction with FDG-PET imaging (51 of 185, 28%). Using calipers with 
measurements in centimeters, the longest diameter of the largest individual or conglomerate 
lymph node mass was measured in the transverse plane and coronal plane (see Figure 1). This 
measurement could lie obliquely, or in any orientation, to ensure ascertainment of the maximal 
diameter. Coronal images were analyzed and reformatted using the open-source software 
OsiriX.14 The quality of the coronal reconstruction was dependent on the slice thickness, ranging 
from 1.2 to 7.5 mm. The quality of coronal reconstructions was assessed using a subjective scale: 
0-poor, 1-fair, 2-good. 
 For the validation cohorts, the measurements were performed in a similar manner as 
described for the training cohort.  At DFCI, the measurements were performed by a single 
medical oncologist (A.K.) and at Mayo by a single board-certified radiologist (D.W.), both 
blinded to patient outcome. Coronal reconstructions were created using OsiriX and TeraRecon 
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(TeraRecon, Inc.) software at DFCI (n=25) and at Mayo (n=13), respectively. Measurements 
were made from dCT at baseline (23 of 38, 61%) and low-dose CT in conjunction with FDG-
PET imaging (15 of 38, 39%).  
 
Statistical analysis 
Survival analyses were performed using the Kaplan–Meier method in SPSS 22 and R 
3.2.3.  Relapse-free survival (RFS) and overall survival (OS) were defined as the time from 
initiation of treatment until progression of disease or relapse (RFS) or until death from any cause 
(OS), respectively. Log-rank tests were used to compare survival differences. A p-value of ≤0.05 
was considered statistically significant.  
The Pearson correlation test assessed the degree of correlation between the maximal 
transverse and coronal diameters. With few deaths, only the association between disease bulk 
and RFS was assessed. To identify the optimal cutoff for the transverse and coronal maximal 
diameters to predict outcome, we identified a range of potential cutoff points (in cm) based upon 
the distribution of the data (between the 10th and 90th percentiles), and examined their 
significance levels using log-rank tests correlating with RFS. The cutoff point resulting in the 
maximal significance level was identified as the optimal cutoff for the transverse and coronal 
dimensions, and this p-value was adjusted by the maximal chi-square method since multiple tests 
were performed.15 Further, we aimed to identify the most predictive “combined” criterion. By 
using concordance probability analysis, we identified the set of maximal diameter cutoffs (i.e. 
transverse > X OR coronal > Y) that most strongly predicted RFS.16 The methods for 
determining bulky disease cutoff, including maximal chi-square method and concordance 
probability analysis, are described in detail in the Supplement.  
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Results 
In total, there were 185 patients who met inclusion criteria for this study. Of the 185 
images examined, 158 (85%) were characterized by the interpreting radiologist as good quality 
for coronal measurement assessment and 27 fair quality (15%). Patient characteristics are shown 
in Table 1.  The median age of patients was 41 years (range, 9 to 85) with slight female 
predominance (57%). Of the histologic subtypes of classical HL, the predominant was the 
nodular sclerosing subtype (78%). Overall, 95% of patients presented with stage II disease by 
Ann Arbor classification. An effusion (pericardial or pleural) or extranodal disease (lung, chest 
wall, or thyroid involvement) was present in a minority of patients.  Using the German Hodgkin 
Study Group system, 71% of patients met criteria for unfavorable risk disease.5  
All patients were treated with standard or novel doxorubicin-based chemotherapy 
regimens (Table 1). The vast majority of patients were treated with ABVD or Stanford V, and 
others were treated with various doxorubicin-containing regimens, including clinical trial 
protocols. A proportion of CD20+ HL patients were treated with rituximab-containing regimens 
(6 of 16). One hundred and fifteen patients (62%) were treated with combined modality therapy 
(CMT) and 70 patients (38%) with chemotherapy alone. 
 
Outcomes  
Of the 185 patients, 23 patients relapsed and 6 patients died after initial therapy (4 deaths 
due to progressive HL after multiple lines of salvage treatment, 1 death from secondary MDS, 
and 1 death of unknown cause). The median follow-up for all patients was 5 years.  The 4-year 
OS was 96.5% (CI 93.2%, 100%) and the 4-year RFS was 86.8% (CI 81.8%, 92.1%).  
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Disease Bulk 
Training Cohort 
In most cases the longest diameter in the transaxial and coronal plane was measured from 
the same lymph node mass; however, in 13 cases the longest diameters were from different sites. 
In univariate analyses, both transverse maximal diameter and coronal maximal diameter were 
significantly associated with RFS, see Supplement Table S1. Using log-rank tests to compare 
RFS, the optimal cutoff point for transverse maximal diameter was 7 cm (P = 0.01, after 
adjustment by the maximal chi-square method P = 0.02). The optimal cutoff point for coronal 
max diameter was 10.5 cm (P = 0.005, after adjustment P = 0.007). Using the concordance 
probability technique to determine optimal combined criterion, the criteria of transverse max 
diameter > 7.0 cm OR coronal max diameter > 7.0 cm was the best predictor for progression (see 
Supplement). Figure 2 demonstrates that the transverse and coronal maximal diameters are 
highly correlated (correlation coefficient R = 0.856, P < 0.001).  
Using cut-point of > 7cm in maximal transverse dimension or maximal coronal 
dimension (>7cm in MTD or MCD), approximately half of the patients are defined as bulky (101 
of 187, 54%). Seventy-three patients had disease bulk > 7.0 cm by transverse criteria and 10 of 
these patients had disease bulk in the transverse plane alone without disease bulk in the coronal 
plane.  Ninety-one patients had disease bulk > 7.0 cm by coronal criteria with 28 patients 
identified as having disease bulk > 7.0 cm on coronal imaging that was not appreciated in the 
transaxial plane. Of the 101 patients with bulky disease (>7cm in MTD or MCD), 83 patients 
had evidence of mediastinal disease bulk, 17 with other sites of supradiaphragmatic bulk, and 1 
with infradiaphragmatic disease bulk, Table 2. 
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Univariate analyses for RFS demonstrated that disease bulk defined as >7cm was 
associated with increased risk for relapse, with similar findings for transverse versus coronal 
plane measurements and for mediastinal versus non-mediastinal disease, Table 2.  The presence 
of bulky disease, defined as > 7cm in maximal transverse dimension or maximal coronal 
dimension (>7cm in MTD or MCD), significantly correlated with RFS. At 4 years, relapse free 
survival for bulky patients was 80.5% (CI 73%, 88.9%) compared to 94.4% (CI 89.1%, 100%) 
for non-bulky, Cox HR 4.21 (CI 1.43, 12.38), P = 0.004, Figure 3A. There was no significant 
difference in OS between patients with bulky versus non-bulky disease (Cox HR 4.63 (CI 0.54, 
40.04), P = 0.126). In an outcomes analysis of bulky patients, Figure 3B, there is no apparent 
difference between RFS for patients uniquely identified in this study with coronal bulk alone 
(coronal > 7cm and transverse ≤7cm) versus traditional definition of bulk using transverse 
measurement (transverse > 7cm) (Cox HR 0.91 (CI 0.33, 2.51), P = 0.846).  
Analysis of bulk stratified by therapy (CMT versus chemotherapy alone) demonstrated 
that patients with bulky disease treated with chemotherapy alone had a particularly unfavorable 
prognosis with 4-year RFS of 55.2% (CI 40.2%, 75.7%). The definition of bulk as >7cm in MTD 
or MCD was a powerful prognostic factor in patients treated with chemotherapy alone. However, 
for patients who received CMT this definition of disease bulk was not prognostic; rather the 
traditional definition of bulky disease (>10cm in transverse plane) delineated a group with 
increased risk of relapse (P=0.001, Figure S1).  
Validation Cohort 
The novel MSK definition of disease bulk (>7cm in MTD or MCD) was prognostically 
relevant among patients who received chemotherapy alone, and, therefore, this prognostic factor 
was examined in an independent validation set of 38 patients with stage II disease treated with 
10 
 
chemotherapy alone (36 with 4-6 cycles of ABVD, 1 with 4 cycles of BCVPP, and 1 with 3 
cycles of MOPP and 3 cycles of ABVD). The median follow-up was 4 years for this cohort. 
Nineteen patients (50%) had disease bulk and 5 patients (13%) were identified to have disease 
bulk on coronal measurement, but not by transverse measurement. Among the 38 patients, there 
were 6 relapse events and 2 deaths, 1 undifferentiated sarcoma 8 years post-treatment in a 53-
year old and 1 bleomycin-related respiratory failure in a 67 year old. Both deaths occurred in 
patients with non-bulky disease. Disease bulk was associated with a trend toward inferior RFS, 
in bulky patients 4-year RFS was 71.1% (CI 52.1%, 97%) versus 4-year RFS of 94.1% (CI 
83.6%, 100%) in non-bulky patients (Cox HR 5.27 (CI 0.62, 45.16), P = 0.09), Figure 5.  
 
Discussion 
The importance of reexamining the definition of bulk is based upon improved 
multidimensional CT data quality and evolving treatment strategies, including reduction and 
elimination of radiotherapy. Previous definitions of disease bulk were formulated in the era when 
combined modality therapy was the standard of care for all ESHL patients.17 Our proposed 
definition of disease bulk (>7cm in transverse or coronal plane) has heightened prognostic 
relevance for patients treated with chemotherapy alone.  To our knowledge, this is the first study 
to analyze the prognostic significance of bulky disease defined in both transverse and coronal 
planes in the era of CT imaging.  This study demonstrates that bulky disease when measured in 
the coronal plane is significantly associated with inferior outcome.  
The early stage risk classification systems including GHSG, EORTC, NCIC, and NCCN 
use MMR and MTR to define mediastinal bulky disease, however, in modern clinical practice 
and in clinical trials, bulky disease is often defined by the maximal transverse diameter of the 
11 
 
largest lymph node mass >10 cm, likely because this measurement is a quick and reproducible 
method of assessing disease bulk on CT imaging. Other studies have suggested alternate 
definitions of mediastinal bulky disease, including lymph node masses greater than 5 cm, 6cm, 
or 7.5 cm.9, 10, 17, 18 Herein the optimal criterion for bulky disease of >7cm in MTD or MCD falls 
within the range of previously reported CT bulk definitions. Our data shows that bulky disease in 
any location, in the mediastinum or an alternate site, is of prognostic value.   
Coronal and sagittal reformations in CT studies provide additional diagnostic and clinical 
information in various clinical settings.19, 20 Evaluation of coronal images in HL is important for 
disease bulk positioned obliquely in the mediastinum or for conglomerate lymph node mass 
extending along the cranio-caudal axis, such as involvement of contiguous cervical, 
supraclavicular, and infraclavicular lymph nodes. We found additional patients (approximately 
30%) with bulky disease were identified using CT coronal reformations that would not have 
otherwise been identified using transaxial imaging alone, identifying additional patients at 
increased risk of relapse. Importantly, patients with coronal-only bulk had similar outcomes 
when compared to patients with bulky disease defined traditionally using transverse 
measurements. This data has the potential to add to the “Lugano classification” system by 
clarifying the importance of measuring disease bulk in the coronal axis in addition to the 
transverse axis.  
OsiriX software was used to create coronal reformats from transaxial CT images in this 
study, however, coronal and sagittal reformations are a routine component of modern multi-
planar CT protocols. Obtaining these measurements on modern pretreatment staging CT scans 
can be easily performed in routine practice.  
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The standard of care for patients with ESHL and bulky mediastinal disease is CMT.21-23  
In the modern treatment of HL, there is interest in limiting or eliminating the use of radiotherapy 
in select patients to decrease long-term radiotherapy-related toxicities. Many clinical trials have 
aimed to eliminate radiotherapy in select ESHL patients, such as the United Kingdom RAPID, 
NCIC HD6, MSK, EORTC/LYSA/FIL H10, and SWOG ESHL trials, and have been limited to 
patients with non-bulky disease.12, 24-26 In the current retrospective analysis, we analyzed risk 
factors for relapse in patients treated with chemotherapy alone versus CMT, and identified a 
novel definition of disease bulk (>7cm in MTD or MCD) that is most prognostically relevant for 
patients treated with chemotherapy alone.  This novel definition was evaluated in an independent 
cohort of patients treated with chemotherapy alone. Unfortunately, the sample size and number 
of relapse events in this validation cohort were few such that the RFS difference in this 
validation cohort did not meet, but trended toward statistical significance (P = 0.09).  The 
findings, however, in the validation cohort were consistent with the training set and demonstrate 
a clinically meaningful difference with most relapse events (5 of 6) occurring among patients 
with disease bulk. These data provide preliminary evidence to potentially caution against 
eliminating radiotherapy in patients with disease >7cm in MTD or MCD as our retrospective 
analysis suggests that chemotherapy alone is associated with poor outcomes in bulky patients (in 
the training set, 4-year RFS of 55.2% (CI 40.2%, 75.7%); in the validation set, 4-year RFS 
71.1% (CI 52.1%, 97%)).  A corollary of these data is that patients without disease bulk per our 
definition appear to have excellent relapse free survival when treated with chemotherapy alone 
(in the training set, 4-year RFS of 97.4% (CI 92.4%, 100%); in the validation set, 4-year RFS 
94% (CI 83.6%, 100%)). Full course chemotherapy, as was commonly administered for patients 
included in this retrospective analysis, is likely not necessary for these non-bulky patients who 
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have an excellent prognosis and would be appropriate candidates for the RAPID or 
CALGB/Alliance 50604 risk-adapted treatment paradigms with abbreviated chemotherapy 
regimens (i.e. 3-4 cycles of ABVD) for PET-negative patients.12, 13 Finally, the training data also 
suggests that patients with very bulky disease with masses >10 cm in the transverse plane have a 
high risk of relapse even when treated with standard CMT, suggesting a role for more intensive 
chemotherapy such as escalated BEACOPP or incorporation of novel agents, such as 
brentuximab vedotin or nivolumab, in this patient population.   
A limitation of this study is that interim and end-of-treatment PET scans were not 
routinely available.  Preliminary data from British Columbia Cancer Agency reports excellent 
outcomes for bulky HL patients who achieve a negative PET scan after full-course ABVD 
without additional consolidative RT and there is an ongoing CALGB/Alliance 50801 study 
exploring interim PET-based risk-adapted therapy in HL patients with disease bulk.27 These 
studies will further clarify whether achievement of an interim or end-of-treatment PET may 
overcome the negative prognostic value of disease bulk at initial presentation. Also the current 
study was inadequately powered to assess association with OS due to few deaths. Furthermore, 
due to a limited number of patients and events, subset analyses were underpowered and 
predominantly univariate analyses were performed. We hope future studies in larger data sets can 
provide external validation.       
In conclusion, our study demonstrates that measurement of bulky disease on coronal 
reformations in addition to standard transaxial measurements identifies additional patients with 
disease bulk, and our data suggests that these patients are potentially at increased risk of relapse 
when treated with chemotherapy alone versus combined modality therapy. Routine review of 
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transverse and coronal reformats on staging CT examinations in ESHL is feasible and has 
clinical impact. 
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Tables 
Table 1. Patient Characteristics of Early Stage Hodgkin Lymphoma, N=185 
 
Patient Characteristic N % 
Median Age  (range) [years] 
 
41 (9-85) 
Female Sex 105 57 
Age < 45  142 77 
Age ≥ 45  43 23 
Pediatric, Age < 18  21 11 
Histologic Subtype  
     Nodular Sclerosing  
     Mixed Cellularity  
     Lymphocyte Rich  
     Classical HL, NOS  
 
144 
22 
2 
17 
 
78 
12 
1 
9 
CD20+ Classical Hodgkin Lymphoma  16 9 
Stage IA  10 5 
Stage IB  0 0 
Stage IIA  122 66 
Stage IIB  53 29 
Pericardial or Pleural Effusion  26 14 
Extranodal disease  26 14 
Lung involvement  13 7 
Chest wall involvement  8 4 
Thyroid involvement  4 2 
ESR >50 if A, ESR > 30 if B, n=167 65 39 
#Nodal Sites >2 defined by GHSG  89 48 
Unfavorable Risk by GHSG*, n=181 128 71 
Treatment 
     Combined Modality Therapy 
     Chemotherapy alone 
 
115 
70 
 
62 
38 
Regimen 
     ABVD regimen 
     Stanford V 
     Other† 
 
107 
34 
44 
 
58 
18 
24 
Abbreviations: HL, Hodgkin lymphoma; GHSG, German Hodgkin Study Group; ESR, 
erythrocyte sedimentation rate. 
*GHSG Unfavorable Risk Criteria: bulky mediastinal mass (≥one-third maximum transverse 
thoracic diameter on Posterior-Anterior Chest X-ray or ≥10cm by CT imaging in axial plane), 
ESR ≥50mm/h or ESR ≥30 mm/h in patients with “B” symptoms, extranodal involvement, or 3 
or more involved lymph node sites (reference) 
†COPP/ABV, AVG, BEACOPP, CHOPE, CHOP, EVA, Rituximab + Chemotherapy,   
and various pediatric protocols such as ABVE-PC. 
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Table 2. RFS at 4 years for bulky disease subgroups defined as >7cm in transverse or coronal 
plane. The corresponding hazard ratios (HR) are reported for the bulky disease subgroups when 
compared to the complementary non-bulky disease subgroup.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bulky Disease Measurement N RFS* HR 
Transverse > 7cm 73 0.80 (0.71 – 0.90) 2.56 (1.09, 5.84) 
Transverse > 7cm only (coronal ≤7cm)  10 0.80 (0.59 – 1.00) 1.75 (0.41, 7.46) 
Coronal > 7cm  91 0.81 (0.73 – 0.89) 3.09 (1.22, 7.83) 
Coronal > 7cm only (transverse ≤7cm) 28 0.82 (0.69 – 0.98) 1.59 (0.59, 4.27) 
Transverse or Coronal > 7cm  
     Mediastinal 
     Non-mediastinal 
          Supradiaphragmatic 
          Infradiaphragmatic 
101 
83 
18 
17 
1 
0.81 (0.73 - 0.89)  
0.82 (0.74 – 0.91) 
0.72 (0.54 – 0.96) 
4.21 (1.43, 12.38) 
Non-bulky (transverse AND coronal ≤7cm) 84 0.94 (0.89 – 1.0)  
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Figure Legends 
 
Figure 1. Representative images of the longest diameters measured using calipers of a right 
cervical mass in A) transverse plane, 2.6 cm and B) coronal plane, 12.1 cm.    
 
Figure 2. Correlation between maximal transverse and coronal measurements with lines for the 7 
cm maximal transverse and coronal cutoffs for disease bulk.  
 
Figure 3. Relapse-free survival by presence of bulky disease.  
A) RFS for non-bulky versus bulky disease (transverse or coronal max diameter > 7cm).  
B) RFS for coronal bulk alone (coronal max measurement > 7cm, transverse max measurement ≤ 
7cm) compared to traditional definition of bulk (transverse max measurement >7cm).  
 
Figure 4. Relapse-free survival by presence of bulky disease (transverse or coronal max 
diameter > 7cm) and treatment (chemotherapy alone (Chemo) vs. combined modality therapy 
(CMT)).   
 
Figure 5. Relapse-free survival by presence of bulky disease (transverse or coronal max 
diameter > 7cm) in validation cohort patients (n=38) treated with chemotherapy alone. 
 
 
 
 





Supplement 
 
Methodology for Determining Optimal Cutoff for Disease Bulk in Early Stage Hodgkin 
Lymphoma 
 
Table S1. Univariate analysis of continuous transverse and coronal max diameters for RFS 
 
  Relapse-free survival 
  HR 95% CI P value 
Transverse maximal diameter 1.22 1.09, 1.37 <0.001 
Coronal maximal diameter 1.17 1.07, 1.27 <0.001 
 
 
Identifying the optimal cutoff of transverse and coronal max diameters for RFS (separately):  
 
Due to the small number of deaths (only 6 in total), we do not use overall survival time but only RFS 
time. Previous studies have variably defined tumor bulk as a prognostic indicator, ranging from 5-10cm. 
Based on the previous results and quantiles of the data (we insist that the cut-off points are between the 
10
th
 and 90
th
 percentiles), we pre-determine some cut-off points for either transverse or coronal max 
diameters (see table below). We examine their significance levels using log-rank tests (for correlating 
with RFS).  
 
Of note, we used a Cox proportional hazards model and log-rank tests to correlate various cut-off points 
with RFS. We did not use ROC analysis which requires a dichotomous endpoint. That is, whether or not 
patient developed progression at a fixed time point (i.e. 4-year RFS). We sought to examine the time to 
relapse, which includes not only the event status, but also when the event occurred. Therefore, a Cox 
proportional hazards model was used, not a ROC analysis. 
 
The cut-off point resulting in the maximal significance level (i.e., smallest p-value) will be identified as 
the optimal cut-off, whose p-value will also be adjusted by the maximal chi-square method due to the fact 
that we have looked at multiple tests.
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We see that the optimal cutoff point for transverse max diameter is 7·0 which yields a p-value of 0·025. 
After the adjustment this p-value is around 0.046. The optimal cutoff point for coronal max diameter is 
10·5 which yields a p-value of 0·0092. After the adjustment this p-value is around 0·014. Note that for the 
coronal max diameter several other cut-off points give close p-values: 6·0, 6·5, 7·0, 9·5, 11.5  and 12·0. 
As a matter of fact, if we use the concordance probability (reference 2) instead of the log-rank test p-value 
to identify the cut-off points, 7·0 will still be the optimal choice for transverse max diameter, but for 
coronal max diameter 4.5 through 8.5 and 9.5are better than 10·5. This implies that an optimal cut-off 
point for coronal max diameter cannot be determined clearly statistically, and several options are 
available. 
 
Table S2. Transverse and coronal max diameter cutoff points and correlation with RFS.  
 
Transverse P-value # of pts > 
cutoff 
 Coronal P-value # of pts > cutoff 
3·0 0·938 168  4·0 0·208 161 
3·5 0·535 152  4·5 0·151 147 
4·0 0·766 148  5·0 0·126 136 
4·5 0·482 133  5·5 0·066 130 
5·0 0·177 121  6·0 0·017 119 
5·5 0·332 111  6·5 0·015 109 
6·0 0·121 100  7·0 0·012 91 
6·5 0·070 88  7·5 0·066 80 
7·0 0·025 73  8·0 0·091 75 
7·5 0·055 57  8·5 0·054 64 
8·0 0·081 46  9·0 0·112 55 
8·5 0·174 37  9·5 0·019 45 
9·0 0·086 33  10·0 0·034 41 
9·5 0·062 26  10·5 0·0092 36 
    11·0 0·042 30 
    11·5 0·016 27 
    12·0 0·0094 20 
       
 
 
Seeking for a “combined” criterion:  
 
We combined the two diameters (transverse and coronal) and identify a better predictor. Although 7·0 and 
10·5 have been identified as the optimal cut-off points individually, their combination may not be the best 
in terms of the predictive capacity (as mentioned above, 10·5 for coronal max diameter, though having 
the smallest log-rank p-value, does not even provide the best predictive capacity separately). Therefore 
we look at several options in case there exist better predictor than “Transverse > 7·0 OR Coronal > 10·5”. 
The table below shows the findings. Note that here the predictive capacity is evaluated quantitatively by 
the concordance probability.
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Table S3. Combined Criterion for disease bulk  
 
Combined Criterion # of pts > cutoff Concordance 
Probability 
Transverse > 7·0 OR Coronal > 4.5 72 0.574 
Transverse > 7·0 OR Coronal > 5.0 72 0.581 
Transverse > 7·0 OR Coronal > 5.5 72 0.601 
Transverse > 7·0 OR Coronal > 6·0 70  0.629 
Transverse > 7·0 OR Coronal > 6·5 68  0.622 
Transverse > 7·0 OR Coronal > 7·0 63  0.654 
Transverse > 7·0 OR Coronal > 7.5 58 0.643 
Transverse > 7·0 OR Coronal > 8.0 57 0.629 
Transverse > 7·0 OR Coronal > 8.5 51 0.619 
Transverse > 7·0 OR Coronal > 9·5 41  0.615 
Transverse > 7·0 OR Coronal > 
10·5 
34  0.619 
Transverse > 7·0 OR Coronal > 
11·5 
25 0.619 
Transverse > 7·0 OR Coronal > 
12·0 
19  0.620 
 
The above results show that “Transverse > 7·0 OR Coronal > 7·0” is the best predictor for progression. 
We caution here that this choice is not associated with a significance level using re-sampling methods, 
nor is it based on any calibration (it is sort of a “pick the winner” strategy).  
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Figure S1. Relapse-free survival by presence of bulky disease with traditional definition (>10cm 
in transverse plane) in the combined modality therapy (CMT) group only. 
 
 
 
